Table 2.
Univariate and multivariate analyses for factors associated with hepatocellular carcinoma development
| Variables | HR (95%CI) | P value |
| Univariate analysis | ||
| Age (by each year) | 1.04 (0.31-1.11) | 0.347 |
| Male sex | 1.61 (0.32-8.04) | 0.564 |
| BMI (by each kg/m2) | 1.00 (0.80-1.25) | 0.982 |
| Habitual drinker | 1.26 (0.25-6.27) | 0.775 |
| Diabetes mellitus | 5.58 (1.19-26.21) | 0.030 |
| HCV-RNA (by each logIU/mL) | 0.87 (0.44-1.72) | 0.696 |
| HCV genotype 1 | 2.90 (0.58-14.35) | 0.195 |
| Stage of fibrosis | 3.59 (1.68-7.68) | 0.001 |
| Grade of inflammation | 4.32 (1.02-18.40) | 0.048 |
| Albumin (by each g/dL) | 0.03 (0.00-0.29) | 0.003 |
| ALT (by each IU/L) | 1.00 (1.00-1.01) | 0.196 |
| Platelet count (by each 104/mL) | 0.75 (0.63-0.90) | 0.002 |
| GGT (by each IU/L) | 1.00 (1.00-1.01) | 0.452 |
| AFP (by each ng/mL) | 1.00 (1.00-1.00) | 0.033 |
| PI use | 2.93 (0.31-27.70) | 0.347 |
| AKR1B10 (by each %) | 1.06 (1.03-1.10) | < 0.001 |
| Multivariate analysis | ||
| AKR1B10 (by each %) | 1.04 (1.03-1.10) | 0.001 |
AFP: α-fetoprotein; AKR1B10: Aldo-keto reductase family1 member B10; ALT: Alanine aminotransferase; BMI: Body mass index; GGT: γ-glutamyl transpeptidase; HCV: Hepatitis C virus; PI: Protease inhibitor.